2003
DOI: 10.1002/ajh.10321
|View full text |Cite
|
Sign up to set email alerts
|

Effects of N‐acetylcysteine on dense cell formation in sickle cell disease

Abstract: The extent to which dense and irreversible sickle cells (ISCs) contribute to vasoocclusive episodes in sickle cell disease remains unclear. N-Acetylcysteine (NAC) inhibits dense cell and ISC formation in sickle erythrocytes in vitro and restores glutathione levels toward normal. A phase II double-blind randomized clinical trial was completed to determine the efficacy of NAC in decreasing dense cell and ISC formation, and vasoocclusive episodes in sickle cell disease. Twenty-one subjects with a history of at le… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
61
1

Year Published

2005
2005
2016
2016

Publication Types

Select...
5
4

Relationship

1
8

Authors

Journals

citations
Cited by 103 publications
(64 citation statements)
references
References 26 publications
2
61
1
Order By: Relevance
“…In this regard, it is very interesting that N-acetylcysteine (NAC) can raise intracellular GSH levels in sickle cells and decrease the formation of irreversibly sickle cells and dense cells in vitro and in vivo [52,53]. In the phase II human NAC trial, 2,400 mg of NAC per day lowered the crisis rate by >60% [53].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In this regard, it is very interesting that N-acetylcysteine (NAC) can raise intracellular GSH levels in sickle cells and decrease the formation of irreversibly sickle cells and dense cells in vitro and in vivo [52,53]. In the phase II human NAC trial, 2,400 mg of NAC per day lowered the crisis rate by >60% [53].…”
Section: Discussionmentioning
confidence: 99%
“…In the phase II human NAC trial, 2,400 mg of NAC per day lowered the crisis rate by >60% [53]. One of the actions of NAC, via decreasing the GSSG/GSH ratio, would be to increase the ubiquitination of spectrin and other targets of its E2/E3 activity.…”
Section: Discussionmentioning
confidence: 99%
“…44 In a phase 2 clinical trial of N-acetylcysteine in SCD patients, administration of the drug decreased the percentage of dense cells, normalized RBC glutathione levels, and decreased the frequency of vaso-occlusive crises. 45 One of the multiple beneficial mechanisms of hydroxyurea in SCD may be reduction of systemic oxidative stress in humans, 46,47 and there is an inverse correlation between hemoglobin F levels and markers of systemic oxidative stress in an SCD mouse model. 48 Trials of antioxidant agents in mouse models of SCD also appear to reduce markers of acute and chronic inflammation.…”
Section: Nadph Oxidase and Ros In Sickle Erythrocytes 2105mentioning
confidence: 99%
“…It is an important finding, because erythrocyte glutathione plays an important role in mitigating the damaging effects of reactive oxygen species (ROS) present in the circulation (Mak et al, 1994) which causes continuous oxidation of haemoglobin within the cytosol of the erythrocyte (Hsieh and Jaffe, 1975). GSH reacts with ROS and degrades hydrogen peroxide and lipid peroxides by glutathione peroxidase or modifies toxic xenobiotics by glutathione S-transferase (Pace et al, 2003). The activity of glutathione peroxidase did not vary significantly in red blood cell haemolysate, liver and kidney, but it was reduced in all treated groups in blood plasma.…”
Section: Discussionmentioning
confidence: 97%